What’s the reality for CDK4/6 inhibitors: Clinical trials or real‐world evidence?
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34672
Abstract: represented in clinical trials, and to frame opportunities to improve patient outcomes. As a result, RWE is not a panacea to resolve all residual uncertainties from clinical trial results, and well ‐ adjusted multivariate analysis… read more here.
Keywords: health; clinical trials; cdk4 inhibitors; reality cdk4 ... See more keywords
Impact of adverse events on survival outcomes in patients treated with CDK4/6 inhibitors for advanced breast cancer
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-025-04836-y
Abstract: CDK4/6 inhibitors have transformed treatment for HR + HER2 − advanced breast cancer (aBC). However, adverse events (AEs) often lead to dose adjustments or discontinuation, potentially impacting outcomes. This study assessed AE incidence and its effect on survival in… read more here.
Keywords: cancer; breast cancer; adverse events; advanced breast ... See more keywords
Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2− breast cancer: an umbrella review
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-023-05516-1
Abstract: Background The use of Cyclin-Dependent kinase 4 and 6 (CDK4/6) inhibitors has profoundly changed the challenge of endocrine therapy (ET) resistance in hormone receptor-positive (HR+)/HER2-negative (HER2−) breast cancer. However, there is currently no comprehensive evaluation… read more here.
Keywords: cancer; breast cancer; therapy; evidence ... See more keywords
Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Sign Up to like & getrecommendations! Published in 2020 at "Current Oncology Reports"
DOI: 10.1007/s11912-020-00917-8
Abstract: Purpose of Review Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have revolutionized the treatment landscape for patients with hormone receptor-positive (HR+) and HER2-negative (HER2−) metastatic breast cancer (MBC). However, optimal therapy after CDK4/6 inhibitors is… read more here.
Keywords: cdk4 inhibitor; cdk4; breast cancer; cdk4 inhibitors ... See more keywords
Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology Reports"
DOI: 10.1007/s11912-022-01251-x
Abstract: Cyclin-dependent kinases (CDKs) are key regulators that play an important role in cell division. Palbociclib, ribociclib and abemaciclib showed significant antitumor activity in several malignancies and, recently, also a myeloprotective effect for trilaciclib when added… read more here.
Keywords: neuroendocrine neoplasms; dependent kinases; cdk4 inhibitors; inhibitors neuroendocrine ... See more keywords
Evolving treatment paradigms after CDK4/6 inhibitors in advanced breast cancer
Sign Up to like & getrecommendations! Published in 2024 at "memo - Magazine of European Medical Oncology"
DOI: 10.1007/s12254-024-01012-5
Abstract: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have transformed the treatment of hormone-receptor-positive, human epidermal growth factor receptor 2‑negative (HR+/HER2−) breast cancer, becoming the standard in first-line endocrine therapy (ET). However, evidence supporting the optimal sequencing post-CDK4/6i… read more here.
Keywords: cdk4 inhibitors; breast cancer; treatment;
Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib.
Sign Up to like & getrecommendations! Published in 2017 at "Breast"
DOI: 10.1016/j.breast.2017.05.016
Abstract: PURPOSE Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors such as palbociclib and ribociclib are associated with distinct adverse effects (AEs) compared to other targeted therapies. This meta-analysis of clinical trials summarizes these agents' toxicity profile.… read more here.
Keywords: palbociclib ribociclib; analysis; toxicity; cdk4 inhibitors ... See more keywords
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer cell"
DOI: 10.1016/j.ccell.2018.03.023
Abstract: CDK4/6 inhibitors are among a new generation of therapeutics. Building upon the striking success of the combination of CDK4/6 inhibitors and the hormone receptor antagonist letrozole in breast cancer, many other combinations have recently entered… read more here.
Keywords: may simple; inhibitors mechanism; cdk4; cdk4 inhibitors ... See more keywords
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer cell"
DOI: 10.1016/j.ccell.2018.11.006
Abstract: Cyclin dependent kinase 4/6 (CDK4/6) inhibitors (CDK4/6i) are effective in breast cancer; however, drug resistance is frequently encountered and poorly understood. We conducted a genomic analysis of 348 estrogen receptor-positive (ER+) breast cancers treated with… read more here.
Keywords: tumor suppressor; resistance cdk4; cdk4 inhibitors; hippo pathway ... See more keywords
CDK4/6 Inhibitors in Combination With Hormone Therapy for HR+/HER2− Advanced Breast Cancer: A Systematic Review and Meta‐analysis of Randomized Controlled Trials
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Breast Cancer"
DOI: 10.1016/j.clbc.2018.04.017
Abstract: Background This meta‐analysis of randomized controlled trials aimed to comprehensively assess the efficacy and toxicity of cyclin‐dependent kinase (CDK) 4/6 inhibitors in advanced breast cancer (ABC) with hormone‐receptor positive (HR+) and human epidermal growth factor… read more here.
Keywords: cdk4 inhibitors; hormone therapy; breast cancer; meta analysis ... See more keywords
Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical breast cancer"
DOI: 10.1016/j.clbc.2021.10.002
Abstract: PURPOSE Everolimus with exemestane (EVE+EXE) was FDA-approved to treat metastatic hormone receptor-positive breast cancer (mHRBC) based on BOLERO-2. However, none of those patients received prior CDK4/6 inhibitors. The purpose of this study is to evaluate… read more here.
Keywords: prior cdk4; eve exe; cdk4; breast cancer ... See more keywords